

1 **Cardiometabolic diseases and associated risk factors in transitional rural**
2 **communities in tropical coastal Ecuador**

3
4 Monsermin Gualan^{1,5¶}, Irina Chis Ster^{2¶}, Tatiana Veloz¹, Emily Granadillo^{1,5}, Luz M. Llangari-Arizo^{1,5},
5 Alejandro Rodriguez¹, Julia A. Critchley³, Peter Whincup³, Miguel Martin^{4,5}, Natalia Romero-
6 Sandoval^{1,5}, Philip J. Cooper^{2,1*}

7
8 ¹ School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador

9 ² Institute of Infection and Immunity, St George's University of London, London, United Kingdom

10 ³ Population Health Research Institute, St George's University of London, London, United Kingdom

11 ⁴ Unidad de Bioestadística, Facultad de Medicina, Universidad Autónoma de Barcelona, Barcelona,
12 Spain

13 ⁵ Grup's de Recerca d' Amèrica i Àfrica Llatines-GRAAL

14
15 *Corresponding author

16 E-mail: pcooper@sgul.ac.uk

17
18 ¶These authors contributed equally to this work

19 **Abstract**

20 **Background**

21 There is a growing epidemic of chronic non-communicable diseases in low and middle-
22 income countries, often attributed to urbanization, although there are limited data from
23 marginalized rural populations. This study aimed to estimate prevalence of cardiometabolic diseases
24 and associated risk factors in transitional rural communities.

25 **Methods**

26 A cross-sectional study of Montubio adults aged 18-94 years living in agricultural
27 communities in a tropical coastal region of Ecuador. Data were collected by questionnaires and
28 anthropometry, and fasting blood was analyzed for glucose, glycosylated hemoglobin, insulin, and
29 lipid profiles. Population-weighted prevalences of diabetes, hypertension, and metabolic syndrome
30 were estimated. Associations between potential risk factors and outcomes were estimated using
31 multilevel regression techniques adjusted for age and sex.

32 **Results**

33 Out of 1,010 adults recruited, 931 were included in the analysis. Weighted prevalences were
34 estimated for diabetes (20.4%, 95% CI 18.3-22.5%), hypertension (35.6%, 95% CI 29.0-42.1%), and
35 metabolic syndrome (54.2%. 95% CI 47.0-61.5%) with higher prevalence observed in women.
36 Hypertension prevalence increased with age while diabetes and metabolic syndrome peaked in the
37 6th and 7th decades of life, declining thereafter. Adiposity indicators were associated with diabetes,
38 hypertension, and metabolic syndrome.

39 **Conclusion**

40 We observed an unexpectedly high prevalence of diabetes, hypertension, and metabolic
41 syndrome in these marginalized agricultural communities. Transitional rural communities are
42 increasingly vulnerable to the development of cardiometabolic risk factors and diseases. There is a
43 need for targeted primary health strategies to reduce the burden of premature disability and death
44 in these communities.

45

46 **Introduction**

47 Low and middle-income countries (LMICs) are undergoing the epidemiologic transition with
48 a shift in the primary causes of death from those attributable to infectious and childhood diseases
49 to chronic non-communicable diseases (NCDs) in the context of rapidly aging populations [1,2].
50 Among NCDs, age-adjusted prevalence of cardiovascular diseases peaked over the period 1960 to
51 1980 in high-income countries (HICs), while an epidemic of these diseases has now emerged in LMICs
52 [3,4], which now account for more than 77% of all deaths attributed to NCDs globally [5].

53 The large increases in prevalence of NCDs in LMICs have been attributed to economic
54 development and urbanization that have resulted in dramatic changes in where and how people live
55 [6] with consequent changes in living conditions, diet, physical activity, and exposures to
56 psychosocial stressors [7]. The emergence of the NCD epidemic in LMICs is having a major impact on
57 utilization of scarce health care resources and poses a significant hurdle to achieving sustainable
58 development goal targets for poverty reduction and prevention of premature death and disability
59 [5].

60 Ecuador is an upper middle-income country in Latin America [8] with a diverse multiethnic
61 population of 17 millions [9], life expectancy of 74 years, and a per capita gross domestic product of
62 US\$6,395 in 2022 [10]. NCDs are now the major causes of death in Ecuador: among the five most
63 important causes of death reported in 2019, 4 were NCDs including ischemic heart disease (14.7%
64 of deaths), type 2 diabetes (T2D) (7.1%), cerebrovascular diseases (6.2%), and hypertension (HTN)
65 (4.9%) [11].

66 The NCD epidemic is increasingly present in rural populations [12] through the influence of
67 urbanization that extends even to the most isolated communities [13–15]. While a rural lifestyle is
68 presumed to reduce the risk of many NCDs because of potentially protective factors - such as
69 consumption of traditional diets high in complex carbohydrates, increased physical activity, and
70 greater social integration [16] - in many rural areas such protective exposures are being lost.
71 Indigenous and other vulnerable population groups living in transitional settings undergoing
72 environmental degradation, urbanization, and the loss of traditional lifestyles, are at increased risk
73 of cardiometabolic diseases [17].

74 We carried out a cross-sectional study of adults living in transitional rural communities of
75 Montubios, a marginalized mestizo-derived ethnicity, in an ecologically vulnerable region of coastal
76 Ecuador to estimate prevalence of cardiometabolic NCDs and associated risk factors. Our findings,
77 showing a high prevalence of cardiometabolic diseases, highlight an unmet need for community-
78 based public health strategies to minimize the growing burden of premature death and morbidity
79 from NCDs among marginalized and indigenous populations living in transitional rural settings.

80 **Methods**

81 **Study design and population**

82 We performed a cross-sectional study of adults living in ten adjacent rural agricultural communities
83 in Abdon Calderon parish, Portoviejo district, Manabí province, in tropical coastal Ecuador. The study
84 area (Fig 1) was traditionally inhabited by Montubios, a Spanish-speaking mestizo-derived ethnicity,
85 geographically restricted to the mountainous regions of coastal Ecuador, and who possess distinct
86 socio-cultural characteristics that distinguish them from the dominant mestizo population.
87 Montubios, along with Indigenous and Afro-Ecuadorians, belong to the poorest ethnic groups in
88 Ecuador and live in communities with important unmet health needs [18]. The study communities
89 were located 10 km from a primary health care facility and 30 km from a regional hospital, in a region
90 of Abdon Calderon parish considered to be highly vulnerable to environmental degradation, and
91 hence deprived of access to services and infrastructure investment. Initial contacts were made with
92 the parish council through local political leaders known to the study team and who acted as
93 gatekeepers. Community representatives were involved at all stages of the study including extensive
94 early meetings to inform study design, objectives, and selection of study site; organisation of
95 meetings to explain study objectives and obtain community consent for the study; planning and
96 organization for individual consent and data collection as well as involvement in the data collection
97 process itself; and community meetings to provide individual results and explain study findings.
98 Communities were selected by convenience sampling. Censuses for each community were drawn up
99 by community representatives specifically for this study. All adults aged 18 years and older living in
100 the communities were invited to participate through community assemblies. Exclusions were those

101 unwilling to provide informed written consent, pregnant women or those having given birth in the
102 previous 3 months. Recruitment took place during scheduled visits to study communities between 6
103 and 10 am from 31st July to 12th September 2021.

104
105 **Fig 1. Geographical Context of the Study Area Showing from Left to Right, Locations in Ecuador of**
106 **Manabí Province, Portoviejo District, and Abdon Calderon Parish.** The figure was designed using
107 shapefiles obtained from the Ecuadorian National Institute of Statistics (INEC),
108 ([https://www.ecuadorencifras.gob.ec/documentos/web-](https://www.ecuadorencifras.gob.ec/documentos/web-inec/Geografia_Estadistica/Micrositio_geoportal/index.html#cartograf-histor)
109 [inec/Geografia_Estadistica/Micrositio_geoportal/index.html#cartograf-histor](https://www.ecuadorencifras.gob.ec/documentos/web-inec/Geografia_Estadistica/Micrositio_geoportal/index.html#cartograf-histor)) and constructed
110 using QGIS version 3.14.

111
112 **Data collection**
113 Data and clinical samples were collected, and clinical measurements performed as follows using
114 standardized protocols: i) questionnaire based on [STEPwise approach to NCD risk factor](#)
115 [surveillance \(STEPS\)](#) [19] to collect data on symptoms, treatments and diagnoses, and potential risk
116 factors; ii) anthropometric measurements including weight (TANITA model BF-60W, Japan), height
117 (SECA model 213, Germany), waist and hip circumferences, and bioimpedance (Bodystat model
118 1500, UK); iii) blood pressure seated after 15 minutes rest using electronic devices (OMRON model
119 7051T, Japan) with daily calibration against a mercury sphygmomanometer and cuffs selected
120 according to upper arm circumference. This was repeated after 5 minutes if systolic blood pressure
121 (SBP) >130 mmHg and/or diastolic blood pressure (DBP) >85 mmHg; and iv) blood after an

122 overnight fast to measure glucose, insulin, glycosylated hemoglobin (HbA1c), cholesterol, high-
123 density lipoprotein (HDL), and triglycerides.

124

125 **Laboratory analyses**

126 HbA1c was measured with fresh anticoagulated venous blood using a fluorescent
127 immunoassay at a field laboratory (iChroma™, Boditech Med Incorporated, South Korea). Serum and
128 plasma were separated by centrifugation and stored at -20C for later analysis at a central laboratory
129 in Quito. Biochemical analyses (cholesterol, HDL, and triglycerides) were done using enzymatic
130 colorimetry assays (Human Diagnostics, Germany). Insulin was analyzed using an immunoenzymatic
131 assay (DIAsource ImmunoAssays, Belgium).

132

133 **Definitions**

134 Definitions for outcomes were: i) Type 2 diabetes (T2D) - clinical history of diabetes treatment
135 and/or glycosylated hemoglobin (HbA1c) $\geq 6.5\%$ [20]; ii) hypertension (HTN) – clinical history of
136 antihypertensive treatment and/or SBP ≥ 140 mm Hg or diastolic blood pressure DBP ≥ 90 mm Hg
137 during 2 separate measurements [21]; and iii) metabolic syndrome (MetS) – 3 or more of the
138 following (using the Harmonized criteria [22]: a) elevated waist circumference of ≥ 94 cm in men and
139 ≥ 88 cm in women [23]; b) triglycerides ≥ 150 mg/dL or treatment with triglyceride-lowering drugs; c)
140 reduced high density lipoprotein (HDL) < 40 mg/dL in men and < 50 mg/dL in women; d) elevated
141 blood pressure $\geq 130/85$ mmHg or treatment with antihypertensives; and e) fasting glucose ≥ 100
142 mg/dL or treatment with glucose-lowering drugs.

143 Definitions for other conditions were: i) Adiposity indicators [24–26]: a) overweight (body
144 mass index ≥ 25) and obesity (BMI ≥ 30); b) abdominal obesity - waist circumference of ≥ 94 cm in
145 men and ≥ 88 cm in women [23]; c) elevated weight-to-height (WHtR) - ≥ 0.5 ; d) body fat (free fat
146 mass) was determined using bioimpedance [27] with increased body fat defined as $\geq 25\%$ for men
147 and $\geq 30\%$ for women; e) visceral adiposity index (VAI) was calculated using a model of adipose
148 distribution corrected for triglyceride and HDL levels [23] with high VAI according to age defined as
149 - age < 30 – VAI > 2.52 ; age ≥ 30 & < 42 – VAI > 2.23 ; age ≥ 42 & < 52 – VAI > 1.92 ; age ≥ 52 & < 66 – VAI
150 > 1.93 ; age ≥ 66 – VAI > 2 ; ii) elevated cholesterol ≥ 200 mg/dl; iii) elevated triglycerides ≥ 150 mg/dL;
151 iv) low HDL < 40 mg/dl in men and < 50 mg/dl in women; v) insulin resistance – Homeostatic Model
152 Assessment (HOMA) index > 2.5 [28,29]; and vi) and previous medical diagnosis (personal history) of
153 heart attack or stroke. Occupation was categorised into 3 categories: agricultural workers, non-
154 agricultural workers, and household chores. Ethnicity was self-identified and categorised into two
155 groups: mestizos and non-mestizos, the latter including Indigenous, Afro-Ecuadorians, Montubios,
156 and White.

157

158

159 **Statistical analysis**

160 T2D, HTN, and MetS were analysed as binary outcomes, while blood pressure, glycemia, and
161 HbA1c were analysed as continuous variables. Because of the three-level hierarchical structure of
162 the data (individuals are nested in households and communities), multilevel regression techniques
163 were used to estimate standard errors and P values. We used age and sex data from the census
164 population in district of Portoviejo (S1 Fig) [9] to derive post-stratification weights to inflate

165 misrepresented groups and reduce effect of overrepresented groups in the sample[30]. We derived
166 prevalences (T2D, HTN, and MetS) and means (SBP, DBP, HbA1c and glycemia) stratified by sex, age
167 (up to power of three terms, i.e. non-linear), and their interactions when statistically significant
168 ($P < 0.05$). We estimated age- and sex-adjusted effects of explanatory variables of interest on
169 prevalence of T2D, HTN, and MetS. Sensitivity analyses were performed for missing data but showed
170 consistent findings to those obtained using complete data. Analyses were exploratory and adjusted
171 only for age and sex rather than the construction of multivariable models. All analyses were done
172 using Stata 18 (version 18, Statacorp, College Station, Texas, USA).

173

174 **Ethics statement**

175 Informed written consent was obtained from each participant and the study protocol was
176 approved by Bioethics Committee of the UTE University (Comité de Ética de Investigación en Seres
177 Humanos de la Universidad UTE, CEISH UTE 2019-1121-03) and by the Ecuadorian Ministry of Public
178 Health (MSP-DIS-2021-0393-O).

179 **Results**

180 **Study population and characteristics**

181 Of 1,525 adults eligible according to the house-to-house census, 1,010 adults were recruited
182 from 10 communities of which 931 (61.0% of those eligible) provided complete data and were
183 included in the analysis. Total and sex-stratified data on socio-demographic factors, indicators of
184 adiposity, biochemical measurements, and clinical history of NCDs are shown in Table 1. The mean
185 age of the study population was 44.7 years (standard deviation 18.1) and 57.5% were women. Most
186 participants lived with a partner (66.1%); 24.3% were functionally illiterate; 48.3% self-identified as
187 non-mestizo with 41.1% identifying as Montubio, 2.3% as Afro-Ecuadorian, and 0.5% as Indigenous.
188 Most (62.6%) men were agricultural workers while 80.9% of women were housewives; recent
189 alcohol consumption was reported by 62.2% (men 77.6% vs. women 50.8%); current smoking was
190 reported by 7.7% (men 17.2% vs. women 0.8%); men were more likely to do physically demanding
191 work and have contact with agrochemicals. Indicators of adiposity were more frequent in women
192 (for example, presence of abdominal obesity [men 49.5% vs. women 66.4%] and elevated body fat
193 [men 93.1% vs. women 97.9%]). Insulin resistance affected 58.6% of the study population and was
194 more frequent in women. Clinical histories of vascular events were reported by 8.7%. Of those with
195 a clinical history of diabetes or hypertension, only 25.8% had evidence of adequate glucose control
196 (S1 Table) and 34.9% had controlled blood pressure (S2 Table), respectively. A comparison of
197 participation and non-participation using our house-to-house census data showed an increase in
198 participation with age (OR 1.02, 95% CI 1.01-1.03) and among women (OR 5.4, 95% CI 3.7-7.8).

199 **Table 1. Baseline frequencies of age and risk factors for chronic non-communicable diseases stratified by sex in 931 adults in a rural parish**
 200 **of Manabi Province, Ecuador.**

Variable	Category	Total (n=931) n (%)	Women (n=535) n (%)	Men (n=396) n (%)
Age distribution and risk factors				
Age group (years)	18-29	229 (24.6)	131 (24.5)	98 (24.8)
	30-39	158 (17.0)	100 (18.7)	58 (14.6)
	40-49	183 (19.7)	107 (20.0)	76 (19.2)
	50-59	149 (16.0)	82 (15.3)	67 (16.9)
	60-69	104 (11.2)	56 (10.5)	48 (12.1)
	≥ 70	108 (11.5)	59 (11.0)	49 (12.4)
Lives with partner	Yes	615 (66.1)	362 (67.7)	253 (63.9)
Functional illiteracy	Yes	226 (24.3)	114 (21.3)	112 (28.3)
Ethnicity	Non-mestizo	450 (48.3)	229 (42.9)	221 (55.8)
	Mestizo	481 (51.7)	306 (57.2)	175 (44.2)
Occupation	Agricultural worker	261 (28.1)	13 (2.4)	248 (62.6)
	Household chores	436 (46.8)	433 (80.9)	3 (0.8)
	Non-agricultural workers	234 (25.1)	89 (16.6)	145 (36.6)
Recent alcohol consumption	Yes	575 (62.2)	270 (50.8)	305 (77.6)
Current smoker	Yes	72 (7.7)	4 (0.8)	68 (17.2)
Physically-demanding work	Yes	319 (34.6)	104 (19.6)	215 (54.8)
Contact with agrochemicals	Yes	253 (27.2)	47 (8.8)	206 (52.0)
Indicators of adiposity and biochemical risk factors				
Obesity	Not overweight (BMI <25)	322 (34.6)	164 (30.5)	159 (40.2)
	Overweight (BMI 25-29)	367 (39.4)	212 (39.6)	155 (39.1)
	Obese (BMI ≥30)	242 (26.0)	160 (29.9)	82 (20.7)
Abdominal obesity	men ≥94cm; women ≥88cm	551 (59.2)	355 (66.4)	196 (49.5)
Elevated WHtR	≥0.5	791 (85.0)	475 (88.8)	316 (79.8)
Elevated body fat	men (≥25%); women (≥30%)	696 (95.9)	412 (97.9)	284 (93.1)
Elevated VAI	See legend	571 (61.3)	368 (68.8)	203 (51.3)

Elevated cholesterol	≥200 mg/dl	445 (47.8)	270 (50.5)	175(44.2)
Elevated triglycerides	≥150 mg/dL	434 (44.6)	257 (48.0)	177 (44.7)
Low HDL	Men <40 mg/dl; women<50 mg/dl	524 (56.3)	367 (68.6)	157 (39.7)
Insulin resistance	HOMA>2.5	546 (58.6)	372 (69.5)	174 (43.9)
Elevated HbA1c	≥6.5%	210 (22.6)	133 (24.9)	77 (19.4)
Self-report of non-communicable diseases or risk factors (history of disease)				
Vascular events (stroke or heart attack)	Yes	81 (8.7)	42 (7.9)	39 (9.9)
Diabetes	Yes	133 (14.3)	95 (17.8)	38 (9.7)
Hypertension	Yes	305 (32.9)	200 (37.4)	105 (26.7)
Elevated cholesterol	Yes	364 (39.2)	237 (44.3)	127 (32.3)

201
202
203
204
205
206

Functional illiteracy was defined as 3 or fewer years of formal schooling [29]. Abbreviations: WHtR – waist-to-height ratio; VAI – visceral adiposity index; HDL – high-density lipoprotein. High VAI - age <30 – VAI >2.52; age ≥30 & <42 – VAI >2.23; age ≥42 & <52 – VAI >1.92; age ≥52 & <66 – VAI >1.93; age ≥66 – VAI >2. Missing data: alcohol consumption (7); current smoker (1); physical demanding work (8); bioimpedance (increased fat %) (205); history of vascular events (3); history of hypertension (3); history of diabetes (3); and history of elevated cholesterol (3).

207 **Population-weighted prevalence of diabetes, hypertension, metabolic**
208 **syndrome, and vascular events**

209 Table 2 shows the crude and population-weighted prevalence of outcomes. Weighted
210 prevalence for T2D, HTN, and MetS were higher among females. Age-prevalence profiles for the 3
211 outcomes by sex are shown in Fig 2 and S1 Table. For T2D, prevalence was greater in women at all
212 ages (Fig 2C) and increased with age reaching a peak of 51% in women and 37% in men at around 75
213 years, after which it declined. Prevalence of HTN increased with age although there was some
214 evidence of an interaction with sex, particularly showing a steep increase in prevalence in women
215 (Fig 2B). For MetS, prevalence increased in both sexes until 57 years in men (70%) and 69 years in
216 women (86%) after which prevalence declined (Fig 2A). Prevalence of MetS was similar in both sexes
217 up to about 40 years, after which prevalence was greater in women. An analysis of 576 participants,
218 for whom blood pressure could be repeated at home, showed a lower average systolic blood
219 pressure in the home setting (average difference, 7.13 mm Hg [95% CI 5.76 - 8.51]) but similar
220 diastolic pressure (average difference 0.17 mm Hg [95% CI -0.82 - 1.16]).

221 **Table 2. Crude and population-weighted prevalence of chronic diseases and means of blood pressure and glucose measures in study**
 222 **population of 931 adults stratified by sex.**

Chronic disease	Total (n=931)		Women (n=535)		Men (n=396)	
	Crude % (n)	Estimated weighted % (95% CI)	Crude % (n)	Estimated weighted % (95% CI)	Crude % (n)	Estimated weighted % (95% CI)
Binary outcomes						
Type 2 Diabetes	26.3 (245)	20.4 (18.3-22.5)	29.5 (158)	24.5 (20.9-28.7)	22.0 (87)	15.8 (12.2-19.4)
Hypertension	44.7 (416)	35.6 (29.0-42.1)	46.2 (247)	37.7 (31.0-44.4)	42.7 (169)	33.3 (26.8-39.7)
Metabolic syndrome	58.0 (540)	54.2 (47.0-61.5)	60.9 (326)	56.2 (47.7-64.7)	54.0 (214)	52.1 (43.3-60.8)
Vascular events	8.7 (81)	4.8 (2.7-6.9)	7.9 (42)	4.6 (2.8-6.4)	9.9 (39)	5.0 (2.2-7.8)
Continuous outcomes						
Systolic blood pressure (mm Hg)	134.0 (245)	131.0 (129.4-132.6)	132.8 (158)	129.2 (127.1-131.2)	135.8 (87)	132.9 (131.0-134.9)
Diastolic blood pressure (mm Hg)	80.8 (416)	79.7 (78.8-80.6)	80.6 (247)	79.5 (78.3-80.6)	80.9 (169)	80.0 (78.7-81.2)
Fasting glucose (mg/dL)	115.0 (540)	111.1 (108.3-113.8)	118.8 (326)	114.6 (110.3-119.0)	109.9 (214)	107.3 (104.5-110.1)
HbA1c (%)	6.4 (81)	6.3 (6.2-6.4)	6.6 (42)	6.4 (6.3-6.6)	6.2 (39)	6.1 (6.0-6.2)

223
 224 Crude sample prevalence and means were derived from clinical history and measurements and weighted estimates (and 95% confidence
 225 intervals [CI]) accounted for household and community clustering and were weighted to the census population at district level (Fig S1).
 226 Chronic diseases definitions: i) Type 2 diabetes - clinical history of diabetes treatment and/or glycosylated hemoglobin (HbA1c) $\geq 6.5\%$; ii)
 227 hypertension – clinical history of antihypertensive treatment and/or SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg during 2 separate measurements
 228 [21]; and iii) metabolic syndrome – using the Harmonized criteria [22]; and iv) vascular events- self-reported history of heart attack or
 229 stroke.
 230

231

232 **Fig 2. Metabolic syndrome, HTN and diabetes: the age-dependent prevalence stratified by gender.** Predictions were from logistic
233 regression of the outcomes on age, gender and their potential interactions accounting for family cluster and weighted for population
234 characteristics.

235 **Risk exposures associated with diabetes, hypertension, and metabolic**
236 **syndrome**

237 Age-and sex-adjusted associations between potential risk factors and disease outcome are
238 shown in Table 3. All outcomes were strongly positively associated with age. There were age-sex
239 interactions on the risks of HTN (P=0.003) and MetS (P=0.001). Among factors associated with T2D
240 were female sex (male vs. female, adj. OR 0.57, 95% CI 0.41-0.80, P=0.001), non-agricultural work
241 (vs. agricultural, adj. OR 1.74, 95% CI 1.01-2.98, P=0.045), HTN (adj. OR 2.09, 95% CI 1.40-3.11), and
242 abdominal obesity (adj. OR 2.85, 95% CI 1.85-4.39). Among factors associated with HTN were
243 household chores (vs. agriculture, adj. OR 3.67, 95% CI 1.71-7.90) or non-agricultural activities (vs.
244 agriculture, adj. OR 1.92, 95% CI 1.13-3.26); history of vascular events (adj. OR 2.45, 95% CI 1.38-
245 4.35); T2D (adj. OR 1.95, 95% CI 1.31-2.90); abdominal obesity (adj. OR 3.12, 95% CI 2.15-4.54); and
246 insulin resistance (adj. OR 3.05, 95% CI 2.10-4.42). MetS was associated with living with a partner
247 (adj. OR 1.55, 95% CI 1.08-2.23), among other factors.

248 **Table 3. Age-and sex adjusted associations between potential risk factors and type-2 Diabetes mellitus, hypertension, and metabolic**
 249 **syndrome in 931 adults.**

Risk factor	Category	Type-2 Diabetes			Hypertension			Metabolic Syndrome		
		n (%)	OR (95% CI)	P value	n (%)	OR (95% CI)	P value	n (%)	OR (95% CI)	P value
Socio-demographic										
Age			1.05 (1.04-1.07)	<0.001		1.10 (1.08-1.11)	<0.001		1.07 (1.06-1.09)	<0.001
Sex	Female	158 (29.5)	1		247 (46.2)	1		326 (60.9)	1	
	Male	87 (22.0)	0.57 (0.41-0.80)	0.001	169 (42.7)	0.80 (0.58-1.12)	0.193	214 (54.0)	0.72 (0.53-0.99)	0.04
Interaction: Age × Sex		-----	-----	-----		0.97 (0.95-0.99)	0.003		0.97 (0.95-0.99)	0.001
Risk exposures										
Lives with partner	No	67 (21.2)	1		124 (39.2)	1		146 (46.2)	1	
	Yes	178 (28.9)	1.46 (1.00-2.13)	0.048	292 (47.5)	1.22 (0.81-1.84)	0.351	394 (64.1)	1.55 (1.08-2.23)	0.017
Functional illiteracy	No	170 (24.1)	1		262 (37.2)	1		382 (54.2)	1	
	Yes	75 (33.2)	0.72 (0.47-1.09)	0.122	154 (68.1)	1.25 (0.83-1.88)	0.296	158 (69.9)	1.04 (0.67-1.60)	0.878
Ethnicity	Others	120 (26.7)	1		224 (49.8)	1		261 (58.0)	1	
	Mestizo	125 (26.0)	1.04 (0.75-1.45)	0.798	192 (39.9)	0.78 (0.55-1.10)	0.158	279 (58.0)	1.21 (0.90-1.64)	0.213
Occupation	Agricultural workers	55 (21.1)	1		111 (42.5)	1		142 (54.4)	1	
	Household chores	139 (31.9)	1.78 (0.87-3.66)	0.116	227 (52.1)	3.67 (1.71-7.90)	0.001	288 (66.1)	1.54 (0.80-2.95)	0.194
	Non-agricultural workers	51 (21.8)	1.74 (1.01-2.98)	0.045	78 (33.3)	1.92 (1.13-3.26)	0.017	110 (47.0)	1.24 (0.78-1.98)	0.370
Recent alcohol consumption	No	122 (35.0)	1		198 (56.7)	1		234 (67.0)	1	
	Yes	120 (20.9)	0.76 (0.52-1.10)	0.146	216 (37.6)	0.80 (0.57-1.12)	0.191	301 (52.3)	0.91 (0.66-1.26)	0.573
Current smoker	No	229 (26.7)	1		388 (45.2)	1		503 (58.6)	1	
	Yes	16 (22.2)	1.08 (0.49-2.38)	0.851	28 (38.9)	0.98 (0.77-1.26)	0.9	37 (51.4)	0.83 (0.44-1.56)	0.561
Physically demanding work	No	162 (26.8)	1		269 (44.5)	1		350 (57.9)	1	
	Yes	81 (25.4)	1.13 (0.77-1.67)	0.53	142 (44.5)	1.10 (0.75-1.61)	0.637	185 (58.0)	0.88 (0.61-1.26)	0.476
Contact with agrochemicals	No	185 (27.3)	1		310 (45.7)	1		397 (58.6)	1	
	Yes	60 (23.7)	0.93 (0.61-1.42)	0.741	106 (41.9)	0.72 (0.48-1.10)	0.126	143 (56.5)	0.90 (0.60-1.36)	0.631
History of chronic diseases or risk factors										
Vascular events	No	217 (25.6)	1		360 (42.5)	1		485 (57.3)	1	
	Yes	27 (33.3)	1.22 (0.71-2.08)	0.467	55 (67.9)	2.45 (1.38-4.35)	0.002	54 (66.7)	1.35 (0.74-2.46)	0.330
Hypertension	No	110 (17.7)	1		-----	-----	-----	-----	-----	-----
	Yes	134 (43.9)	2.08 (1.44- 3.01)	0.001	-----	-----	-----	-----	-----	-----
Diabetes	No	-----	-----	-----	312 (39.2)	1		-----	-----	-----
	Yes	-----	-----	-----	103 (77.4)	3.01 (1.79-5.07)	<0.001	-----	-----	-----
Elevated cholesterol	No	114 (20.2)	1		213 (37.8)	1		284 (50.4)	1	
	Yes	130 (35.7)	1.71 (1.23-2.36)	0.001	203 (55.5)	1.56 (1.08-2.24)	0.018	255 (70.1)	1.62 (1.15-2.27)	0.005

Chronic diseases (history and/or clinical measurements)										
Hypertension	No	79 (15.3)	1		-----	-----	-----	-----	-----	-----
	Yes	166 (39.9)	2.09 (1.40-3.11)	<0.001						
Diabetes	No	-----	-----	-----	250 (36.4)					
	Yes	-----	-----	-----	166 (67.8)	1.95 (1.31-2.90)	0.001			
Nutritional and laboratory measures										
Obesity	Not overweight (BMI<25)	42 (13.0)	1		93(28.9)	1		80 (24.8)	1	
	Overweight (BMI 25-29)	113 (30.8)	2.29 (1.48-3.56)	<0.001	179 (48.8)	1.99 (1.28-3.10)	0.002	248 (67.6)	5.85 (3.86-8.88)	<0.001
	Obese (BMI≥30)	90 (37.2)	3.25 (1.96-5.40)	<0.001	144 (59.5)	4.20 (2.55-6.93)	<0.001	212 (87.6)	27.6 (15.8-48.2)	<0.001
Abdominal obesity	No	44 (11.6)	1		94 (24.7)	1		-----	-----	-----
	Yes (men≥94 cm; women≥88 cm)	201 (36.5)	2.85 (1.85-4.39)	<0.001	322 (58.4)	3.12 (2.15-4.54)	<0.001	-----	-----	-----
Elevated cholesterol	No	103 (21.2)	1		174 (35.8)	1		241 (49.6)	1	
	Yes (≥200 mg/dL)	142 (31.9)	1.09 (0.77-1.54)	0.629	252 (54.4)	1.28 (0.89-1.84)	0.175	299 (67.2)	1.37 (0.98-1.92)	0.069
Elevated triglycerides	No	99 (19.9)	1		186 (37.4)	1		-----	-----	-----
	Yes (≥150 mg/dL)	146 (33.6)	1.66 (1.20-2.32)	0.003	230 (53.0)	1.26 (0.90-1.76)	0.172	-----	-----	-----
Low HDL	No	93 (22.9)			174 (42.8)			-----	-----	-----
	Yes (men<40 mg/dL; women<50 mg/dL)	152 (29.0)	1.32 (0.93-1.87)	0.126	242 (42.8)	1.40 (0.97-2.02)	0.069	-----	-----	-----
Insulin resistance	No	46 (11.9)	1		123 (31.9)	1		127 (33.0)	1	
	Yes (HOMA>2.5)	199 (36.4)	3.77 (2.41-5.90)	<0.001	293 (53.7)	3.05 (2.10-4.42)	<0.001	413 (75.6)	8.77 (6.15-12.51)	<0.001

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Odd ratios (ORs) and 95% confidence intervals were estimated using logistic regression and accounting for household and community clustering and weighted for population structure. Age² was strongly associated with all 3 outcomes: type-2 Diabetes (OR 0.9986, 95% CI 0.9982-0.9990, P=0.001), hypertension (OR 0.9993, 95% CI 0.9988-0.9999, P=0.028), and metabolic syndrome (OR 0.9992, 95% CI 0.9986-0.9997), P<0.001). Associations between outcomes and risk exposures, clinical history, and laboratory measures were adjusted for the sociodemographic variables shown in Table 1 (including age and age² [all outcomes], sex [all outcomes], and the interaction between age and sex [hypertension and the metabolic syndrome]). Functional illiteracy was defined as 3 or fewer years of formal schooling [31]. Outcome definitions: i) Type 2 diabetes - clinical history of diabetes treatment and/or glycosylated hemoglobin (HbA1c) ≥6.5%; ii) hypertension – clinical history of antihypertensive treatment and/or ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg during 2 separate measurements [21]; and iii) metabolic syndrome – using the Harmonized criteria [22]; and iv) vascular events- self-reported history of heart attack or stroke. Abdominal obesity was measured using waist circumference. Missing data: alcohol consumption (7); current smoker (1); physical demanding work (8); Missing data: alcohol consumption (n=7); current smoker (1); physical demanding work (8); history of: vascular events (3), respiratory disease (3), kidney disease (3), elevated cholesterol (3), diabetes (3) and hypertension (3); and bioimpedance (increased fat %) (205). Abbreviation: BMI – body mass index; HDL – high-density lipoprotein; HOMA - Homeostatic Model Assessment index.

265 **Associations between indicators of adiposity and measurements of**
266 **systolic and diastolic blood pressure, fasting glucose, and glycosylated**
267 **hemoglobin**

268 Means of systolic blood pressure (SBP) and diastolic blood pressure (DBP), fasting capillary
269 blood glucose and glycosylated hemoglobin (HbA1c) in the study population and stratified by sex are
270 shown in Table 2.

271 There were significant interactions between age and sex for all 4 measurements ($P < 0.005$)
272 (Fig 3 and S3 Table). Predicted values for SBP increased with age being greater in men up to 50
273 years after which values were greater in women (Fig 3A). Predicted DBP increased with age up to
274 50 years and then declined, showing a similar sex interaction as for SBP (Fig 3B). Predicted values
275 of fasting glucose increased with age reaching a plateau after 50 years (Fig 3C): levels were similar
276 in both sexes up to 30 years after which levels diverged becoming greater in women. A similar
277 pattern was seen for HbA1c (Fig 3D). Strong associations were observed between a variety of
278 adiposity indicators and blood pressure levels and glucose measurements (S3 Table).

279
280 **Fig 3. SBP, DBP, glycemia and HbA1c predicted levels stratified by gender.** Predictions were from
281 regression on age, gender and their potential interactions accounting for family cluster and
282 weighted for population characteristics.

284 Discussion

285 In this cross-sectional study, we estimated prevalence and associated risk factors for
286 cardiometabolic NCDs in adults living in transitional rural communities in tropical Ecuador. These
287 communities, located in an ecologically vulnerable region of coastal Ecuador, were traditionally
288 inhabited by a marginalized population group, the Montubios. Our data showed a high weighted
289 prevalence of T2D, HTN, and MetS affecting 20.4%, 35.6%, and 54.2%, respectively, of inhabitants in
290 these communities. The majority (74.2%) of those with a doctor diagnosis T2D had poorly controlled
291 disease and 14% were unaware of their condition. Similarly, over one-quarter of those with HTN
292 (26.6%) were unaware of their diagnosis before the study. Over 8% of the study population had a
293 history of vascular events (stroke or heart attack). NCDs were more common in females, and largely
294 increased with age, becoming very common at extremes of age (e.g. 70% with HTN by age 80).

295 Weighted prevalence of T2D, HTN and MetS observed here was greater than might be
296 expected from the findings of previous surveys from Ecuador [29,32,33] and elsewhere in Latin
297 America [34–36]. Previous studies have estimated T2D prevalence of 8.7% in the Latin American
298 region [34] and 4.7% in adult Ecuadorians. [37] The most recent national survey from 2018 estimated
299 a T2D prevalence of 7.1%, indicating a likely temporal trend of increasing prevalence among
300 Ecuadorian adults [32]. Other studies have shown that marginalized population groups, particularly
301 indigenous populations, appear to be particularly vulnerable to high rates of T2D: 70% of studies in
302 indigenous populations evaluated in a recent systematic review reported prevalence greater than
303 10%[38]. A recent study of Afro-Ecuadorian adults living in conditions of severe poverty in a rural
304 region of coastal Ecuador, estimated a T2D prevalence of 6.8% [39]. Although differences in
305 estimated prevalence between studies could be explained partly by differences in disease

306 definitions, mean age of study population, and study design, our estimate of 20.4% was
307 unexpectedly high.

308 The age-standardized prevalence of HTN declined over the period 1975-2015 in HICs while
309 tending to increase in many LMICs with an overall doubling of numbers of people with HTN globally
310 because of population growth and ageing [6]. Prevalence of HTN in Latin America and the Caribbean
311 declined over the same period [6] although age-standardized prevalence remained high (35.4%) in
312 the region in 2019 [35]. Our estimate of 35.6% HTN prevalence is close to this value and is similar to
313 that reported among Afro-Ecuadorians (36%), another marginalized group living in rural transitional
314 coastal communities [15] among whom HTN was considered the most important cause of death [40].
315 However, our estimate of HTN prevalence was more than double that reported among adults living
316 in urban and rural settings elsewhere in the country [29,41,42].

317 MetS is known to predict sudden death [43] and increases markedly the risk of cardiovascular
318 diseases [44] - even one to two components of the syndrome have been associated with increased
319 mortality [45,46]. A population-based survey of adults from 7 Latin American cities including Quito
320 estimated prevalence of MetS ranging from 14% in Quito to 27% in Barquisimeto, Venezuela [36].
321 Within Latin America a high prevalence of MetS has been reported among indigenous populations
322 including 46.7% in the Amazon region of Venezuela [47] and 37% in Brazil, although in Brazil the
323 prevalence in 6 surveys of Indigenous groups varied markedly between 11% in Parana and 66% in
324 Matto Grosso [48]. Our estimate of 54.2% was similar to that obtained (55.7%) in a house-to-house
325 survey of adults living in a (Cholo-)Montubio community in the southern coastal region of Ecuador
326 [49], but greater than that reported (42%) in urban and rural areas in the central Andean region of
327 the country [50] and in a national survey (31.2%) [33]. Differences in prevalence estimates within

328 Ecuador could represent differences in definitions, sampling methods, as well as differing population
329 risks for individual components of the syndrome.

330 Rural communities undergoing rapid changes relating to urbanization processes are of
331 particular relevance for studies examining potential causal links between changes in risk behaviors,
332 development of risk factors, and emergence of cardiometabolic disease. The coastal region of
333 Ecuador, where we did this study, is of particular interest because of unique geographic, cultural,
334 and socio-economic characteristics, likely to affect distributions of risk factors and NCD prevalence.
335 Montubios are recognized in Ecuador as a distinct mestizo-derived ethnicity and represent a
336 historically excluded group living in rural, often low mountainous and isolated regions (<500 m) of
337 coastal Ecuador [51,52]. Montubio communities adhere closely to traditional values, being a
338 patriarchal culture based on tight kinship ties, conservative values, and a close relationship with the
339 land. However, Montubio communities are presently undergoing a rapid transition to a more
340 westernized lifestyle [53], and many communities are found in ecologically vulnerable environments.
341 Traditionally, the inhabitants of these communities lived as agriculturalist (as day-laborers or
342 cultivators of smallholdings) with seasonal work on large coffee plantations. The region consists of
343 mountainous terrain currently undergoing rapid degradation relating to deforestation and soil
344 erosion, resulting in poorly fertile soils for agriculture. There is a high vulnerability to rapid runoff
345 and landslides and the area has been designated as of extreme ecologic risk by the district council
346 and excluded from government and municipal investment in infrastructure and basic services
347 including health care. These factors likely have contributed to a process of acculturation, likely
348 accelerated by occupational shifts from the land to services generally provided outside the
349 communities; the effects of the migration of the young in search of employment either temporarily
350 or permanently; and with the introduction of electricity, the impact of technological innovations

351 such as television and digital media. Such changes have occurred over a period of less than a
352 generation (road access and electricity were introduced 15-20 years previously) and have been
353 accompanied by increased sedentarism and a shift in diet to include increasing quantities of
354 processed foods high in fat, sugar, and salt [29,54] that can be acquired cheaply in local stores.

355 Several studies have shown rural populations in LMICs to have healthier cardiometabolic
356 profiles than urban residents, an effect attributed to greater physical activity more than dietary
357 effects [55–57]. The sedentarization of rural occupations likely has led to changes in cardiometabolic
358 risk factors profiles and disease risk to resemble urban populations. The prevalence of vascular
359 events (8.7% with stroke or heart attack) observed here is somewhat lower than reported from
360 another Montubio population further south in Coastal Ecuador where stroke prevalence increased
361 from 14.1% to 35.2% between 2003 and 2012 [49,58]. Possible explanations are poorer survival rates
362 or the more recent emergence of an unhealthy profile of cardiometabolic risk factors in our
363 population. Environmental degradation may have compounded such effects through more rapid
364 shifts in occupation, diets, and activity levels. Rapid changes in diet and physical activity affecting a
365 population exposed to chronic under-nutrition in childhood likely will saturate metabolic capacity in
366 adulthood [59] and increase vulnerability to the premature development of cardiometabolic risk
367 factors and disease.

368 Indigenous groups in Latin America appear to be at particular risk of cardiometabolic NCDs
369 particularly diabetes [38] in the context of acculturation, deforestation, and environmental
370 degradation [17]. Other rural marginalized groups might be expected to suffer similar risks although
371 available data are limited [60]. An additional challenge for these populations is inadequate health
372 care access which further contributes to the burden of disability and premature death. Lack of access
373 to health care results in delays in diagnosis and limits treatment access. Even where there is health

374 access, a lack of education and financial resources often limits availability of and adherence to
375 treatment which often needs to be provided regularly for life. This was seen in the present study by
376 the observation that greater than 65% of those with a previous doctor diagnosis of T2D or HTN had
377 poorly controlled glucose or blood pressure, respectively. Lower socioeconomic conditions in LMIC
378 populations have been consistently linked to cardiometabolic NCD prevalence as well as to MetS or
379 its individual components [3,39,61–63]. Further, a rational public health strategy for NCD control
380 and prevention in resource-poor rural populations will require community-based interventions,
381 ideally through primary health care (or community health worker networks) where available and
382 targeted to the specific risk factors and pathologies prevalent in specific populations [64,65].

383

384 **Limitations**

385 Data collection targeted a marginalized population living in a restricted geographic setting
386 where we believed there to be major unmet health needs. The data can be generalized to similar
387 populations living in coastal Ecuador in conditions of extreme ecologic and social vulnerability. Non-
388 participation of healthier members of the communities could have led to overestimation of
389 estimates, likely related to more active, healthier individuals being away for work. Survey non-
390 participation was largely explained by absence of working-age adults (20-40 years), particularly men,
391 because of salaried work commitments outside the communities. Under-representation of adults
392 aged 20-40 years that was apparent based on a comparison of age-structure between our house-to-
393 house-census and the projected census population for the district, was adjusted for using weighted
394 estimates. The use of questionnaires to collect data on clinical histories and risk factors may be

395 subject to recall or social desirability bias although we used standardized clinical and laboratory
396 measurements to measure risk factors and outcomes where possible.

397

398 **Conclusion**

399 We observed a high prevalence of T2D, HTN, and MetS in marginalized Montubio
400 communities in a rural region of coastal Ecuador. Environmental degradation and accelerated
401 urbanization occurring in these transitional communities over a period of approximately 20 years,
402 with increased out-migration, occupational shifts, and changes in diet and physical activity are likely
403 to be important causes of these NCDs. Our data indicate that marginalized rural populations
404 undergoing a rapid transition from traditional to more modern lifestyles in Ecuador and elsewhere
405 in Latin America suffer an unacceptable burden of preventable morbidity. This burden might be
406 reduced by targeted public health strategies including the training and adequate resourcing of
407 community health workers.

408

409 **Acknowledgments**

410 The authors thank participant communities and their representatives for their co-operation,
411 and the support of technicians and health professionals from Universidad Internacional del
412 Ecuador and the CAMERA study.

413

414 **References**

- 415 1. Shu J, Jin W. Prioritizing non-communicable diseases in the post-pandemic era based on a
416 comprehensive analysis of the GBD 2019 from 1990 to 2019. *Sci Rep.* 2023;13:13325. doi:
417 10.1038/s41598-023-40595-7.
- 418 2. Omran AR. Ar, Omran. “The epidemiologic transition theory revisited thirty years later.”
419 (1998). *World Health Statistics Quarterly.* 1998;51: 99–119. Available:
420 [https://apps.who.int/iris/bitstream/handle/10665/330604/WHSQ-1998-51-n2-3-4-](https://apps.who.int/iris/bitstream/handle/10665/330604/WHSQ-1998-51-n2-3-4-eng.pdf?isAllowed=y&sequence=1)
421 [eng.pdf?isAllowed=y&sequence=1](https://apps.who.int/iris/bitstream/handle/10665/330604/WHSQ-1998-51-n2-3-4-eng.pdf?isAllowed=y&sequence=1)
- 422 3. Ezzati M, Pearson-Stuttard J, Bennett JE, Mathers CD. Acting on non-communicable diseases
423 in low- and middle-income tropical countries. *Nature.* 2018;559: 507–516.
424 doi:10.1038/s41586-018-0306-9
- 425 4. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369
426 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for
427 the Global Burden of Disease Study 2019. *Lancet.* 2020;396: 1204–1222. doi:10.1016/S0140-
428 6736(20)30925-9
- 429 5. World Health Organization. Noncommunicable diseases. 16 Sep 2022 [cited 19 Feb 2023].
430 Available: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>
- 431 6. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan MJ, et al. Worldwide trends in
432 blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based
433 measurement studies with 19·1 million participants. *Lancet.* 2017;389: 37–55.
434 doi:10.1016/S0140-6736(16)31919-5
- 435 7. Juma K, Juma PA, Shumba C, Otieno P, Asiki G. Non-Communicable Diseases and
436 Urbanization in African Cities: A Narrative Review. In: Anugwom, E.E. and Awofeso, N., Eds.,

- 437 Public Health in Developing Countries—Challenges and Opportunities, IntechOpen,
438 London. 2020. <https://doi.org/10.5772/intechopen.89507>
- 439 8. The World Bank. World Bank Country and Lending Groups – World Bank Data Help Desk.
440 [cited 17 Oct 2023]. Available:
441 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
442 [and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
- 443 9. Instituto Nacional de Estadística y Censos. Resultados Censo de Población. [cited 2 Apr
444 2018]. Available: <https://www.ecuadorencifras.gob.ec/censo-de-poblacion-y-vivienda/>
- 445 10. Banco Central del Ecuador. PUB - PIB Per Cápita. [cited 17 Oct 2023]. Available:
446 [https://sintesis.bce.fin.ec/BOE/OpenDocument/2303281959/OpenDocument/opendoc/ope-](https://sintesis.bce.fin.ec/BOE/OpenDocument/2303281959/OpenDocument/opendoc/opendocument.jsp?logonSuccessful=true&shareId=0)
447 [nDocument.jsp?logonSuccessful=true&shareId=0](https://sintesis.bce.fin.ec/BOE/OpenDocument/2303281959/OpenDocument/opendocument.jsp?logonSuccessful=true&shareId=0)
- 448 11. Instituto Nacional de Estadística y Censos. Estadísticas de defunciones generales en el
449 Ecuador. 2020 [cited 27 Feb 2023]. Available:
450 <https://www.ecuadorencifras.gob.ec/defunciones-generales-2020/>
- 451 12. Gupta R. Convergence in urban–rural prevalence of hypertension in India. *Journal of Human*
452 *Hypertension* 2016 30:2. 2015;30: 79–82. doi:10.1038/jhh.2015.48
- 453 13. Alvarez MO, Sanchez JPD. An Overview of Urbanization in Ecuador under Functional Urban
454 Area Definition. *REGION*. 2018;5: 38–48. doi:10.18335/region.v5i3.235
- 455 14. Rodriguez A, Vaca MG, Chico ME, Rodrigues LC, Barreto ML, Cooper PJ. Lifestyle domains as
456 determinants of wheeze prevalence in urban and rural schoolchildren in Ecuador: cross
457 sectional analysis. *Environmental Health*. 2015;14: 15. doi:10.1186/1476-069X-14-15

- 458 15. Rodriguez A, Vaca M, Oviedo G, Erazo S, Chico ME, Teles C, et al. Urbanisation is associated
459 with prevalence of childhood asthma in diverse, small rural communities in Ecuador. *Thorax*.
460 2011;66: 1043–1050. doi:10.1136/thoraxjnl-2011-200225
- 461 16. Boakye K, Bovbjerg M, Schuna J, Branscum A, Varma RP, Ismail R, et al. Urbanization and
462 physical activity in the global Prospective Urban and Rural Epidemiology study. *Sci Rep*.
463 2023;13: 290. doi:10.1038/s41598-022-26406-5
- 464 17. Kramer CK, Leitão CB, Viana L V. The impact of urbanisation on the cardiometabolic health of
465 Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the
466 Brazilian Health registry. *Lancet*. 2022;400: 2074–2083. doi:10.1016/S0140-6736(22)00625-0
- 467 18. Instituto Nacional de Estadística y Censos. Pobreza por Ingresos. 2010 [cited 15 May 2023].
468 Available: <https://www.ecuadorencifras.gob.ec/pobreza-diciembre-2022/>
- 469 19. World Health Organization. Standard STEPS instrument. 2020 [cited 26 May 2023].
470 Available: [https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-](https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps/instrument)
471 [tools/steps/instrument](https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps/instrument)
- 472 20. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of
473 Medical Care in Diabetes—2022. *Diabetes Care*. 2022;45: S17–S38. doi:10.2337/dc22-S002
- 474 21. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH
475 Guidelines for the management of arterial hypertension. *J Hypertens*. 2018;36: 1953–2041.
476 doi:10.1097/HJH.0000000000001940
- 477 22. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing
478 the Metabolic Syndrome. *Circulation*. 2009;120: 1640–1645.
479 doi:10.1161/CIRCULATIONAHA.109.

- 480 23. González-Chávez A, Gómez-Miranda JE, Elizondo-Argueta S, Rangel-Mejía M del P, Sánchez-
481 Zúñiga M de J. Guía de práctica clínica de síndrome metabólico. Asociación Latinoamericana
482 De Diabetes. 2019;9. doi:10.24875/ALAD.19000381
- 483 24. Amato MC, Giordano C. Visceral Adiposity Index: An Indicator of Adipose Tissue Dysfunction.
484 Int J Endocrinol. 2014;2014: 1–7. doi:10.1155/2014/730827
- 485 25. Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index
486 (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a
487 Caucasian Sicilian population. Lipids Health Dis. 2011;10: 183. doi:10.1186/1476-511X-10-
488 183
- 489 26. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American
490 Association of Clinical Endocrinologists and American College of Endocrinology
491 Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity.
492 Endocrine Practice. 2016;22: 1–203. doi:10.4158/EP161365.GL
- 493 27. Deurenberg P, van der Kooij K, Evers P, Hulshof T. Assessment of body composition by
494 bioelectrical impedance in a population aged greater than 60 years. Am J Clin Nutr. 1990;51:
495 3–6. doi:10.1093/ajcn/51.1.3
- 496 28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis
497 model assessment: insulin resistance and beta-cell function from fasting plasma glucose and
498 insulin concentrations in man. Diabetologia. 1985;28:412-9. doi: 10.1007/BF00280883.
- 499 29. Freire W, Ramírez-Luzuriaga MJ, Belmont P, Mendieta MJ, Romero N, Sáenz K, et al. Tomo I:
500 Encuesta Nacional de Salud y Nutrición de la población ecuatoriana de cero a 59 años.
501 ENSANUT-ECU 2012. Quito-Ecuador; 2014.

- 502 30. Little RJA. Post-Stratification: A Modeler's Perspective. *J Am Stat Assoc.* 1993;88: 1001.
503 doi:10.2307/2290792
- 504 31. Dirección Nacional de Análisis e Información Educativa. Tasa de Analfabetismo Funcional.
505 2014.
- 506 32. Ministerio de Salud Pública del Ecuador. Encuesta STEPS Ecuador 2018 - Vigilancia de
507 enfermedades no transmisibles y factores de riesgo. Quito; 2018. Available:
508 <https://www.salud.gob.ec/wp-content/uploads/2020/10/INFORME-STEPS.pdf>
- 509 33. Pérez-Galarza J, Baldeón L, Franco OH, Muka T, Drexhage HA, Voortman T, et al. Prevalence
510 of overweight and metabolic syndrome, and associated sociodemographic factors among
511 adult Ecuadorian populations: the ENSANUT-ECU study. *J Endocrinol Invest.* 2021;44: 63–74.
512 doi:10.1007/s40618-020-01267-9
- 513 34. International Diabetes Federation. IDF Diabetes Atlas | Tenth Edition. 2021 [cited 20 Oct
514 2023]. Available: <https://diabetesatlas.org/>
- 515 35. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective
516 interventions for elevated blood pressure and hypertension. *Nat Rev Cardiol.* 2021;18: 785–
517 802. doi:10.1038/s41569-021-00559-8
- 518 36. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al.
519 Prevalence of the Metabolic Syndrome in Latin America and its association with sub-clinical
520 carotid atherosclerosis: the CARMELA cross sectional study. *Cardiovasc Diabetol.* 2009;8: 52.
521 doi:10.1186/1475-2840-8-52
- 522 37. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes
523 Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and

- 524 projections for 2045. *Diabetes Res Clin Pract.* 2022;183: 109119.
525 doi:10.1016/j.diabres.2021.109119
- 526 38. Fischer-Claussen C, Papadimos E, Barr EL, Magliano DJ, Warne D, Maple-Brown L, et al. Type
527 2 Diabetes among Indigenous adult populations. *IDF Diabetes Atlas report on diabetes*
528 *among Indigenous Peoples.* 2022. Available: [https://diabetesatlas.org/idfawp/resource-](https://diabetesatlas.org/idfawp/resource-files/2022/12/IDF-Indigenous-Peoples-Report.pdf)
529 [files/2022/12/IDF-Indigenous-Peoples-Report.pdf](https://diabetesatlas.org/idfawp/resource-files/2022/12/IDF-Indigenous-Peoples-Report.pdf)
- 530 39. Puig-García M, Caicedo-Montaño C, Márquez-Figueroa M, Chilet-Rosell E, Montalvo-Villacis
531 G, Benazizi-Dahbi I, et al. Prevalence and gender disparities of type 2 diabetes mellitus and
532 obesity in Esmeraldas, Ecuador: a population-based survey in a hard-to-reach setting. *Int J*
533 *Equity Health.* 2023;22: 124. doi:10.1186/s12939-023-01939-x
- 534 40. Anselmi M, Avanzini F, Moreíra J-M, Montalvo G, Armani D, Prandi R, et al. Treatment and
535 control of arterial hypertension in a rural community in Ecuador. *Lancet.* 2003;361: 1186–
536 1187. doi:10.1016/S0140-6736(03)12918-2
- 537 41. Ortiz R, Torres M, Peña Cordero S, Alcántara Lara V, Supliguicha Torres M, Vasquez Procel X,
538 et al. Factores de riesgo asociados a hipertensión arterial en la población rural de Quingeo
539 Ecuador. *Revista Latinoamericana de Hipertensión.* 2017;12: 95–103. Available:
540 <https://www.redalyc.org/articulo.oa?id=170252187004>
- 541 42. Ortiz P, Vásquez Y, Arévalo E, Van der Stuyft P, Londoño Agudelo E. Gaps in Hypertension
542 Management in a Middle-Income Community of Quito-Ecuador: A Population-Based Study.
543 *Int J Environ Res Public Health.* 2022;19: 5832. doi:10.3390/ijerph19105832
- 544 43. Tirandi A, Carbone F, Montecucco F, Liberale L. The role of metabolic syndrome in sudden
545 cardiac death risk: Recent evidence and future directions. *Eur J Clin Invest.* 2022;52.
546 doi:10.1111/eci.13693

- 547 44. Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA.
548 Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors.
549 Diabetes Metab Res Rev. 2022;38. doi:10.1002/dmrr.3502
- 550 45. Eberly LE, Prineas R, Cohen JD, Vazquez G, Zhi X, Neaton JD, et al. Metabolic Syndrome. Risk
551 factor distribution and 18-year mortality in the multiple risk factor intervention trial.
552 Diabetes Care. 2006;29: 123–130. doi:10.2337/diacare.29.01.06.dc05-1320
- 553 46. Hess PL, Al-Khalidi HR, Friedman DJ, Mulder H, Kucharska-Newton A, Rosamond WR, et al.
554 The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in
555 Communities Study. J Am Heart Assoc. 2017;6. doi:10.1161/JAHA.117.006103
- 556 47. Quiroz D, Quiroz D, Bognanno FJ, Marin M. Prevalence of metabolic syndrome and risk
557 factors Kariña ethnicity, Bolivar State, Venezuela. Revista Científica Ciencia Médica. 2016;20:
558 7–20. Available: http://www.scielo.org.bo/pdf/rccm/v21n1/en_v21n1_a02.pdf
- 559 48. de Siqueira Valadares LT, de Souza LSB, Salgado Júnior VA, de Freitas Bonomo L, de Macedo
560 LR, Silva M. Prevalence of metabolic syndrome in Brazilian adults in the last 10 years: a
561 systematic review and meta-analysis. BMC Public Health. 2022;22:327. doi: 10.1186/s12889-
562 022-12753-5.
- 563 49. Del Brutto OH, Zambrano M, Peñaherrera E, Montalván M, Pow-Chon-Long F, Tettamanti D.
564 Prevalence of the metabolic syndrome and its correlation with the cardiovascular health
565 status in stroke- and ischemic heart disease-free Ecuadorian natives/mestizos aged ≥ 40
566 years living in Atahualpa: A population-based study. Diabetes & Metabolic Syndrome:
567 Clinical Research & Reviews. 2013;7: 218–222. doi:10.1016/j.dsx.2013.10.006
- 568 50. Baldeón ME, Felix C, Fornasini M, Zertuche F, Largo C, Paucar MJ, et al. Prevalence of
569 metabolic syndrome and diabetes mellitus type-2 and their association with intake of dairy

- 570 and legume in Andean communities of Ecuador. PLoS One. 2021;16: e0254812.
571 doi:10.1371/journal.pone.0254812
- 572 51. Gobierno Autónomo Descentralizado de la Parroquia Abdón Calderón. Plan de Desarrollo y
573 Ordenamiento Territorial de la Parroquia “Abdón Calderón” 2019-2023. 2019. Available:
574 <https://gadabdoncalderon.gob.ec/manabi/>
- 575 52. Cevallos Ruales F. La cultura montubia, patrimonio inmaterial del ecuador una oportunidad
576 para el turismo cultural. I Congreso de: CIENCIA, SOCIEDAD E INVESTIGACIÓN
577 UNIVERSITARIA. 2017. Available:
578 <https://repositorio.pucesa.edu.ec/handle/123456789/2097>
- 579 53. Roitman K. Hybridity, Mestizaje, and Montubios in Ecuador. QEH Working Papers. 2008;165.
580 Available: <https://ideas.repec.org/p/qeh/qehwps/qehwps165.html>
- 581 54. Popkin BM, Ng SW. The nutrition transition to a stage of high obesity and noncommunicable
582 disease prevalence dominated by ultra-processed foods is not inevitable. *Obes Rev.*
583 2022;23:e13366. doi: 10.1111/obr.13366.
- 584 55. Mennen L, Mbanya J, Cade J, Balkau B, Sharma S, Chungong S, et al. The habitual diet in rural
585 and urban Cameroon. *Eur J Clin Nutr.* 2000;54: 150–154. doi:10.1038/sj.ejcn.1600909
- 586 56. Taylor R, Badcock J, King H, Pargeter K, Zimmet P, Fred T, et al. Dietary intake, exercise,
587 obesity and noncommunicable disease in rural and urban populations of three Pacific Island
588 countries. *J Am Coll Nutr.* 1992;11: 283–293. doi:10.1080/07315724.1992.10718229
- 589 57. Gregory CO, Dai J, Ramirez-Zea M, Stein AD. Occupation Is More Important than Rural or
590 Urban Residence in Explaining the Prevalence of Metabolic and Cardiovascular Disease Risk
591 in Guatemalan Adults1. *J Nutr.* 2007;137: 1314–1319. doi:10.1093/jn/137.5.1314

- 592 58. Del Brutto OH, Santamaría M, Zambrano M, Peñaherrera E, Pow-Chon-Long F, Del Brutto VJ,
593 et al. Stroke in Rural Coastal Ecuador: A Community-Based Survey. *International Journal of*
594 *Stroke*. 2014;9: 365–366. doi:10.1111/ijis.12102
- 595 59. Miranda JJ, Barrientos-Gutiérrez T, Corvalan C, Hyder AA, Lazo-Porras M, Oni T, et al.
596 Understanding the rise of cardiometabolic diseases in low- and middle-income countries.
597 *Nat Med*. 2019;25: 1667–1679. doi:10.1038/s41591-019-0644-7
- 598 60. Agbonlahor O, DeJarnett N, Hart JL, Bhatnagar A, McLeish AC, Walker KL. Racial/Ethnic
599 Discrimination and Cardiometabolic Diseases: A Systematic Review. *J Racial Ethn Health*
600 *Disparities*. 2023. doi:10.1007/s40615-023-01561-1
- 601 61. Volaco A, Cavalcanti AM, Filho RP, Precoma DB. Socioeconomic Status: The Missing Link
602 Between Obesity and Diabetes Mellitus? *Curr Diabetes Rev*. 2018;14: 321–326.
603 doi:10.2174/1573399813666170621123227
- 604 62. Blanquet M, Legrand A, Pélissier A, Mourgues C. Socio-economics status and metabolic
605 syndrome: A meta-analysis. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*.
606 2019;13: 1805–1812. doi:10.1016/j.dsx.2019.04.003
- 607 63. Boissonnet C, Schargrotsky H, Pellegrini F, Macchia A, Marcet Champagne B, Wilson E, et al.
608 Educational inequalities in obesity, abdominal obesity, and metabolic syndrome in seven
609 Latin American cities: the CARMELA Study. *European Journal of Cardiovascular Prevention &*
610 *Rehabilitation*. 2011;18: 550–556. doi:10.1177/1741826710389418
- 611 64. Allen L, Williams J, Townsend N, Mikkelsen B, Roberts N, Foster C, et al. Socioeconomic
612 status and non-communicable disease behavioural risk factors in low-income and lower-
613 middle-income countries: a systematic review. *Lancet Glob Health*. 2017;5: e277–e289.
614 doi:10.1016/S2214-109X(17)30058-X

615 65. Haque M, Islam T, Rahman NAA, McKimm J, Abdullah A, Dhingra S. Strengthening Primary
616 Health-Care Services to Help Prevent and Control Long-Term (Chronic) Non-Communicable
617 Diseases in Low- and Middle-Income Countries. Risk Manag Healthc Policy. 2020;Volume 13:
618 409–426. doi:10.2147/RMHP.S239074
619
620

621 **Supporting information**

622 **S1 Fig: Age distribution in the study sample compared to that of the Portoviejo population,**
623 **stratified by gender. Data were obtained from the 2010 census [9].**

624
625 **S1 Table. Clinical history of diabetes and presence of hyperglycemia (Hb1Ac \geq 6.5%) at time of**
626 **survey.**

627
628 **S2 Table. Clinical history of hypertension and presence of elevated blood pressure (>140/90 mm**
629 **Hg) at time of survey.**

630
631 **S3 Table. Age-and sex adjusted associations between indicators of adiposity and systolic and**
632 **diastolic blood pressure (mm Hg), glycosylated hemoglobin (HbA1c) (%), and fasting glucose**
633 **(mg/dL) in 931 adults.** Estimates and 95% confidence intervals (CI) were derived from linear
634 regression analyses and accounted for household and community clustering and were weighted for
635 population structure. Associations, i.e. the adjusted mean differences between groups defined by
636 indicators of adiposity were adjusted for the sociodemographic variables shown in the Table
637 (including age and age² [all outcomes], age³ [HbA1c and fasting glucose], sex [all outcomes], and
638 the interaction between age and sex [all outcomes]). Abbreviations: BP – blood pressure; WHtR –
639 waist-to-height ratio; VAI – Visceral adiposity index. Definitions for indicators of adiposity:
640 Overweight (BMI \geq 25); abdominal obesity (waist circumference of \geq 94 cm in men and \geq 88 cm in
641 women); increased body fat (men (\geq 25%, women (\geq 30%); WHtR (\geq 0.5); elevated VAI (age <30 – VAI
642 >2.52; age \geq 30 & <42 – VAI > 2.23; age \geq 42 & <52 – VAI >1.92; age \geq 52 & <66 – VAI > 1.93; age \geq 66
643 – VAI > 2). Missing data: increased fat (205).

644

645 **S1 Data. Raw data used for analyses.**

646

647 **Data availability**

648 The data analyzed in this study are provided within the supporting information.





